Background. Although trichuriasis affects millions of children worldwide, recommended drugs lack efficacy and new treatment options are urgently needed. Ivermectin has promising potential to complement the anthelminthic armamentarium.
Soil-transmitted helminthiases are caused by the endoparasitic nematodes Ascaris lumbricoides, hookworm, and Trichuris trichiura. Almost half a billion persons are infected with T. trichiura alone, with children harboring the most intense infections [1, 2] . In children, T. trichiura infections can cause malnutrition, iron-deficiency anemia, and reduced physical and cognitive development, causing the major burden of disease among this most vulnerable age group [2] [3] [4] . Preventive chemotherapy in the form of population-based deworming programs is an effective public health measure to reduce morbidity [3, 4] .
The efficacy of current first-line drugs against trichuriasis, the benzimidazoles albendazole and mebendazole as monotherapies and single dose-regimens, used in preventive chemotherapy programs, is unsatisfactory, displaying only low cure rates (CRs) and egg-reduction rates (ERRs) [5] [6] [7] . Furthermore, drug resistance, a major issue in veterinary medicine, is also of concern in humans, because these compounds have been in use for decades [5, 7, 8] . Hence, alternative treatments need to be studied for efficacy and safety, notably in the demographic groups most heavily affected.
Ivermectin, an antiparasitic drug used against a wide range of diseases, including onchocerciasis, lymphatic filariasis, strongyloidiasis, and scabies, is a promising candidate for treatment of soil-transmitted helminthiases [9] [10] [11] [12] . Mass drug administration programs with ivermectin alone against onchocerciasis, or in combination with albendazole against lymphatic filariasis, have been shown to lower the prevalence of trichuriasis in endemic areas [13] [14] [15] . Ivermectin revealed efficacy comparable to the benzimidazoles against T. trichiura infection when administered alone, and in combination with either albendazole or mebendazole performed even better [16] [17] [18] [19] [20] . Owing to its broad antiparasitic spectrum, ivermectin would be an attractive agent within integrated treatment approaches in settings where multiparasitism is the norm [21] . Its coadministration with albendazole has recently been added to the World Health Organization (WHO) essential medicines list for the treatment of soil-transmitted helminth (STH) infection [22] .
Despite its use for decades, important characteristics of ivermectin still remain unknown, for example, the optimal dosage of this drug against T. trichiura infection. Moreover, with the exception of a single retrospective study in 15 infants with scabies [23] , the safety of this drug has never been thoroughly studied in children <5 years of age. Presently ivermectin is approved for use in children weighing ≥15 kg or ≥5 years of age. However, preventive chemotherapy is recommended as a public health intervention for all children, including preschool-aged children (PSAC) and school-aged children (SAC), living in STHendemic areas [24] . Our trial intended to close these knowledge gaps by characterizing the dose-response relationship for efficacy of ivermectin and its safety in PSAC and SAC.
METHODS

Study Design and Participants
This randomized, placebo-controlled, single-blind trial was conducted in seven villages near Azaguié, Agboville department, southern Côte d'Ivoire, from 19 September to 3 November 2017. Children 2-12 years of age who were T. trichiura positive were considered eligible for the trial. To avoid high CRs in the placebo arms [25] , only children with T. trichiura infection intensities of >60 eggs per gram of stool (EPG) in PSAC and 100 EPG in SAC were included. Excluded from the trial were children with any systemic illness (eg, symptomatic malaria or severe anemia, defined as hemoglobin <70 and <80 g/L in PSAC and SAC, respectively [26] ), those who had received any anthelminthic treatment within the past 4 weeks, and those who were allergic to ivermectin.
Ethical Considerations
Ethical clearance was obtained from the National Ethics Committee of the Ministry of Health in Côte d'Ivoire (reference No. 052//MSHP/CNER-kp), and the Ethics Committee of Northwestern and Central Switzerland (reference No. 2017-00250). Written informed consent was obtained from all parents and guardians of the children after they had attended an information meeting and they had been encouraged to ask questions in an open discussion forum. SAC gave verbal assent.
Randomization and Treatment
Three-milligram ivermectin tablets were obtained from Elea, Argentina. For PSAC, minitablets were produced at the University of Basel. Minitablets were manufactured by milling the 3 mg tablets, with subsequent recompaction to white, round, uncoated minitablets containing 0.5 mg of ivermectin.
PSAC (aged 2-5 years) were randomly assigned placebo or ivermectin at 100 or 200 µg/kg. SAC (aged 6-12 years) were randomly assigned to placebo or ivermectin at 200, 400, of 600 µg/kg. Study-site investigators were aware of the study-group assignment, and participants and laboratory technicians were blinded. Randomization was performed using a computer-generated code with varying random blocks sizes of four or eight children for SAC and three or six for PSAC, stratified by their baseline infection intensities (light or moderate plus heavy infection, according to WHO guidelines) [27] .
Study Procedures
At baseline, children provided two stool samples, obtained if possible on two consecutive days or otherwise within a maximum of five days. From each sample, duplicate Kato-Katz thick smears were prepared and examined for STH (T. trichiura, A. lumbricoides, and hookworm) and Schistosoma mansoni eggs [28] . Egg counts were recorded, and infections were classified as light, moderate, or heavy [27] . For quality control, 10% of the slides were randomly chosen and reexamined. If discordant egg counts were observed slides were reread for a third time and the results discussed until consensus was reached [29, 30] .
Before treatment, children were physically examined and questioned for clinical symptoms. Adverse events were assessed through active asking and graded at 3, 24, and 72 hours after treatment. To assess organ toxicity, complete blood cell count and hepatic and renal function tests were conducted by means of venous blood samples at baseline and 72 hours after treatment. Treatment efficacy was assessed 14-21 days after treatment by examining additional quadruplicate Kato-Katz thick smears. At the end of the study, all children who remained positive for any STH infection were treated with albendazole (400 mg) [4] . All excluded children who were positive for any STH infection also received albendazole.
Outcomes
The primary outcome was CR against T. trichiura infection. Secondary end points were drug safety, geometric mean ERR against T. trichiura, and CR and ERR against other STH species and S. mansoni.
Statistical Analysis
The main aim of this study was to elucidate the dose-response relationship of ivermectin against T. trichiura. Computer simulations showed that with 40 children enrolled in each of the study arms (0, 200, 400, and 600 µg/kg or 0, 100, and 200 µg/kg ivermectin) the dose-response prediction model had a median precision (half of the 95% confidence interval [CI]) of 10%, assuming associated CRs of 2.5%, 30%, 50%, and 70% for 0, 200, 400, and 600 µg/kg ivermectin, respectively [31] .
All data were entered twice into a database (Access 2016; Microsoft), compared using EpiInfo software, version 3.3.2 (Centers for Disease Control and Prevention), and analyzed using R software, version 3.4.1 (www.r-project.org). An available-case analysis was performed, including all children who were randomized and provided stool samples at follow-up.
The CR was calculated as the percentage of egg-positive children at baseline who become egg-negative after treatment at follow-up. The EPG was assessed by calculating the mean egg counts from the Kato-Katz thick smears, multiplied by 24.
The geometric mean egg counts were calculated for the seven treatment groups before and after treatment as follows: e 1/n ∑ log(x + 1) − 1 (where x is egg counts) to determine the corresponding ERR ([1 − geometric mean egg output after treatment/geometric mean egg output at baseline] × 100). Ordinary nonparametric bootstrap resampling (5000 replicates) was used to calculate 95% CIs for the ERR against T. trichiura infections.
We performed an available-case analysis including all randomized children with primary end-point data. We evaluated dose-response curves by fitting nonlinear E max models for CRs and ERRs separately for each age group, using the DoseFinding package in R.
RESULTS
Baseline Characteristics
A total of 810 PSAC and 974 SAC were screened for eligibility; 703 children with complete parasitological data at baseline were T. trichiura negative, and 491 did not provide two stool samples. Of those who were T. trichiura positive, 242 were excluded owing to very light infection intensity, below the thresholds for eligibility mentioned above, and 46 children were oversampled.
We randomly assigned 130 PSAC to the three and 172 SAC to the four treatment arms of their respective age groups (Figure 1 ). At follow-up, 10 children (3.3%; range among treatment groups 0.0%-4.7%) were absent or did not provide stool samples. Fourteen children who provided only a single sample were included in the available case analysis.
Demographic and parasitological data at baseline for all children who received treatment are presented in Table 1 . The treatment arms were balanced by T. trichiura infection intensities according to geometric means of EPG and WHO cutoffs [27] , as well as with respect to age, height, and weight. One arm of the SAC subgroup consisted of considerably more boys than girls (28 vs 15) ; the other arms were balanced with respect to sex.
Among PSAC, 113 (86.9%) had a light T. trichiura infection (<1000 EPG), and 17 (13.1%) had a moderate infection (1000-9999 EPG); no heavy T. trichiura infection was recorded in PSAC. Among SAC, 137 (79.7%) had a light T. trichiura infection, 34 (19.8%) had a moderate infection, and one (0.6%) was heavily infected (≥10 000 EPG).
Efficacy Against T. trichiura
The CRs and ERRs against T. trichiura among the 292 children with follow-up data are shown in Table 2 . The estimated dose-response curves of the E max model are shown in Figure 2 . The E max models estimated low CRs for all treatment arms, with the 50% effective dose lying outside the dose range tested. For ERRs, the models predicted increasing efficacy with ascending doses, but the observed effect was small.
Among PSAC, CRs against T. trichiura were similar between the placebo arm and the highest ivermectin dose administered; In SAC, CRs against T. trichiura were 2.4% in the treatment arms receiving placebo (95% CI, 0.1%-11.2%) and ivermectin at 200 (0.1%-11.2%) or 400 µg/kg (0.1%-11.5%). The 600 µg/kg dose resulted in a slightly higher CR (12.2%; 95% CI, 4.8%-32.3%).
The geometric mean ERRs in SAC were 31.9% (95% CI, −0.3% to 56.3%) in the placebo arm and 54.2% (35.5%-68.4%), 47.6% (21.2%-67.6%), and 66.3% (44.7%-80.3%) in the treatment arms receiving ivermectin at 200, 400, or 600 µg/kg, respectively. The arithmetic mean ERRs were −8.8% (95% CI, −54.9% to 17.0%), 34.3% (12.5%-51.2%), 50.0% (19.5%-65.5%), and 37.7% (13.4%-53.6%), respectively, in these respective treatment arms.
Efficacy Against Other Helminth Infections
Data on efficacy against other helminth infections are presented in Table 2 . Owing to the small sample sizes, no 95% CIs were calculated for CR and ERR (ERRs based on arithmetic means are presented in Supplementary Table 1 ). All 23 PSAC receiving either 100 or 200 µg/kg of ivermectin had their A. lumbricoides infection cured. Similar results were observed in SAC; only two of the 35 children receiving ivermectin at any dose were still positive for A. lumbricoides at follow-up (range of CRs among treatment arms, 87.5%-100%). The ERRs were 100% in ivermectin-treated children, compared with 84.4% and 68.3% in the PSAC and SAC placebo arms, respectively.
Few S. mansoni infections were observed in PSAC. Among the 44 SAC infected with S. mansoni, there was no difference between the efficacy of ivermectin at any dose studied and placebo. The CRs were 27.3% for placebo treated children and 10.0%-30.8% for ivermectin-treated children, and ERRs were also similar among the different trial arms.
Safety
Safety assessment included 302 children, although not every child was present at every time point (Table 3) . Only mild clinical symptoms were reported by the children and their parents/ guardians, with most symptoms occurring before treatment (70 symptomatic children; 23.2%). Decreasing numbers of adverse events were recorded at subsequent examination time points, with symptoms in 27 (8.9%), 14 (4.7%) and 11 (3.9%) of the children at 3, 24, and 72 hours after treatment, respectively.
Among PSAC, clinical symptoms after treatment were more common in the placebo arm than in children receiving either dose of ivermectin (13.2% vs 11.5%), whereas the opposite trend was seen with SAC (20.7% vs 13.2%). However, this difference was more pronounced before treatment (26.3% vs 15.3%). The most common symptoms after treatment in SAC were diarrhea (7.9% in placebo vs 6.9% in any ivermectin arm) and in PSAC headache (7.9% vs 6.6%, respectively) and abdominal pain (2.6% vs 13.2%). No allergic reaction to the drug was observed.
Safety data from blood samples were available for 274 children (119 PSAC and 155 SAC). No new-onset severe anemia [26] , thrombocytopenia (cell count, <50 000/µL) or neutropenia (cell count, <500/µL) were observed 72 hours after treatment. No acute kidney injury, defined as a >1.5-fold increase over the baseline creatinine level [32] , was observed. No child showed an • CID 2018:67 (15 October) • 1253 Ivermectin Against Trichuris trichiura increase in transaminase levels to twice the upper limit of normal or an increase of bilirubin surpassing the upper limit of normal.
DISCUSSION
Trichuriasis is a neglected tropical disease of considerable public health significance [1] . Despite the high burden of disease, current first-line treatments have unacceptably low efficacy against this parasite in treatment regimen used in preventive chemotherapy [5] . Furthermore, a recent network meta-analysis indicated that the efficacy of albendazole and mebendazole against T. trichiura has decreased over the almost 50 years of their extensive use [7] .
Albendazole-ivermectin has recently been added to the WHO essential medicine list to fill this gap and to be able to provide a broad-spectrum treatment covering all STH species, including T. trichiura. However, the optimal dose of ivermectin remains to be identified, with all studies evaluating its monotherapy or combination chemotherapy conducted to date using a standard dose of 200 µg/kg [16] [17] [18] 20] .
Moreover, SAC have traditionally been the main target population for preventive chemotherapy programs [2] , but WHO guidelines highlight the importance of including other highrisk populations, such as PSAC, within the framework of these public health efforts [4] . Because neither optimal dosage of ivermectin nor its safety in PSAC were known, ascending doses of ivermectin known to be safe in the adult population were studied for the first time in children 2-5 years of age. Surprisingly, ivermectin showed low CRs at all doses tested in PSAC and SAC, even at 600 µg/kg, a dose tested for the first time against T. trichiura infections. In both age groups, however, moderate ERRs were observed at increasing dosages. Yet, only ivermectin at 400 µg/kg in SAC performed above the WHO reference efficacy (≥50%) for T. trichiura, based on the arithmetic mean [30, 33] .
The weak performance of ivermectin against trichuriasis in the present trial contrasts with the findings of the three studies by Wen et al [19] , Beach et al [34] , and Belizario et al [16] , who reported CRs of 66.7%, 44.3%, and 35.1%, respectively using the standard dose of 200 µg/kg. These conflicting results might be explained by spatiotemporal differences, because these studies were performed 10-20 years ago in the Americas and Asia; moreover, two studies included patients with significantly less intense infections [19, 34] , and one study also included adults [19] .
The significantly higher CRs and ERRs for albendazole-ivermectin than for albendazole alone highlight the important contribution of ivermectin to the therapeutic effect of the combination [35] . Synergism of the two drug classes most likely occurs on the parasite level, since previous studies did not observe alteration in plasma concentrations of the individual drugs when administered in combination, compared with the administration of each drug alone [36] . The inhibition by ivermectin of membrane transporter proteins acting as efflux pumps on helminth cells, such as p-glycoprotein, causing accumulation of albendazole and its metabolites within the parasite cells, might be the underlying mechanism of this phenomenon [37] .
High efficacy of ivermectin against A. lumbricoides is in agreement with previous findings [16, 19] . Our data do not suggest any schistosomicidal property of ivermectin.
Ivermectin is well known for its excellent safety profile [9, 11] . In the present study, it was well tolerated in both age groups at all doses studied. Data from blood samples taken at baseline and 72 hours after treatment did not reveal any significant hematotoxic, nephrotoxic, or hepatotoxic effect. The incidence of adverse events was especially low among PSAC, a finding in accordance with the results of Bécourt et al [23] , who reported only two benign and transient adverse events in 15 infants treated with ivermectin for scabies. However, the small sample size is a limitation of our study, and conclusions on safety should be drawn with caution. Another limitation is that we explored dosages only up to 600 µg/kg, but an increase of >three-fold the recommended dose did not seem ethically and scientifically justified. Finally, owing to the low number of moderate and heavy infections, our results are not generalizable to all infection intensities, but only to mild infections.
In summary, extending ivermectin treatment to children <5 years of age is a clear asset of the current study. The good tolerability of ivermectin at 200 µg/kg in PSAC and 600 µg/kg in SAC suggests that these doses can be used safely in the respective age groups. Ivermectin doses of 100-200 µg/kg in PSAC and 200-600 µg/kg in SAC have low CRs similar to that that for placebo in the treatment of T. trichiura infections. At the highest doses administered, only moderate ERRs were observed. Because ivermectin doses as high as 2000 µg/kg seem to be safe in the adult population [38] [39] [40] [41] , the evaluation of higher doses of ivermectin against trichuriasis might be considered. However, the promising results of its coadministration with albendazole or mebendazole [16] [17] [18] 20] , hinting at synergism, highlight the important role of ivermectin in combination chemotherapy rather than as monotherapy. Ivermectin combination chemotherapy should therefore be explored in the treatment of STH infections.
